ApoptoSENS — Death-Resistant Cells

One of seven SENS damage categories proposed by Aubrey de Grey ¹. ApoptoSENS names the problem: senescent cells that should die, don’t, because they upregulate pro-survival Senescent Cell Anti-Apoptotic Pathways (SCAPs). The therapeutic strategy is to selectively re-induce apoptosis in these cells — an approach now called senolysis, operationalized via senolytics.

This page is a navigational framework overlay. Quantitative findings live on the atomic entity pages linked throughout; this page provides the SENS-specific framing and points to the evidence base.

Parent framework: sens-damage-categories · Counterpart hallmark frame: cellular-senescence (verified 2026-05-04)

Position in the SENS map

The seven SENS damage categories and their repair strategies:

#	Category	Damage	Repair strategy	Hallmark counterpart
1	RepleniSENS	Cell loss	Stem cells / tissue engineering	stem-cell-exhaustion
2	OncoSENS	Telomere-driven cancer	WILT	genomic-instability / telomere-attrition
3	ApoptoSENS	Death-resistant senescent cells	Senolytics	cellular-senescence
4	MitoSENS	mtDNA mutations	Allotopic expression	mitochondrial-dysfunction
5	LysoSENS	Intracellular aggregates	Bacterial enzyme delivery	loss-of-proteostasis
6	AmyloSENS	Extracellular aggregates	Immunotherapy	loss-of-proteostasis
7	GlycoSENS	ECM crosslinks	AGE-breaker compounds	(no direct hallmark)

Why senescent cells resist apoptosis

Senescent cells exist in a paradox: they are chronically exposed to pro-apoptotic signals from their own sasp (IL-6, IL-8, reactive oxygen species) yet survive. The explanation is SCAPs — cell-type-specific upregulation of the anti-apoptotic arm of the bcl-2-family-signaling network ².

The SCAP concept was established by Zhu, Tchkonia, Kirkland and colleagues in 2015 ². Key finding: SCAPs are not universal — the dominant survival node differs by cell type. This means no single senolytic can be expected to clear all senescent cell types.

Cell-type-specific SCAPs identified across three primary studies (full data on senolytics and individual BCL-2 family protein pages):

Cell type	Primary SCAP nodes	Lead senolytic
HUVECs (endothelial)	bcl-xl, EFNB1/EFNB3	quercetin, navitoclax, a1331852
IMR90 fibroblasts	Triple combination: bcl-2 + bcl-xl + bcl-w	navitoclax
Human preadipocytes	Ephrins (EFNB1/3), EPH receptors, PI3KCD, PAI-2, p21	dasatinib

IMR90 correction note: Zhu 2016 Fig 4A-B established that for IMR90 fibroblasts, no single BCL-2 family member is sufficient for senolysis — the full BCL-2 + BCL-xL + BCL-W triple combination is required ³. Yosef 2016 ⁴ showed BCL-W + BCL-xL dual knockdown produced ~53% viability reduction in IMR90s with each alone having only minor effect, but did not test the triple. These findings together establish multi-target BCL-2 family inhibition as the IMR90-specific requirement. See bcl-2, bcl-xl, bcl-w for detail.

The upstream activators of SCAPs include the p53-pathway and nf-kb signaling (both elevated in senescence), and the pi3k-akt-pathway (driven by ephrin signaling in preadipocytes). These pathways create the feed-forward loop that sustains the resistance phenotype.

Therapeutic translation: senolytics

ApoptoSENS is the most clinically advanced SENS category as of 2026 ⁵. The full evidence base for senolytic agents lives on senolytics (verified 2026-05-04). This section tours the evidence organized by the SENS therapeutic logic.

Step 1 — Proof of concept: genetic clearance

Before any drug was available, conditional genetic clearance of p16^INK4a^+ senescent cells in INK-ATTAC transgenic mice demonstrated that removing senescent cells extends healthspan ⁶ and, in naturally aged mice, extends median lifespan ⁷. These experiments established the causal claim: it is senescent cell presence (not just the upstream damage that caused senescence) that drives aging phenotypes. See cellular-senescence for the full evidence summary.

Dimension	Status
Pathway conserved in humans?	yes (BCL-2 family apoptosis machinery)
Phenotype conserved in humans?	partial — senescent cell burden increases with age in humans; causal contribution assumed but not genetically proven
Replicated in humans?	in-progress (pharmacological senolysis trials)

Step 2 — First pharmacological senolytics: D+Q

Dasatinib + Quercetin (D+Q) was the first drug combination rationally designed as a senolytic — targeting the preadipocyte SCAP (dasatinib, via ephrin disruption) and the HUVEC SCAP (quercetin, via BCL-xL / EFNB1) in a complementary polypharmacological strategy ².

Full compound data: dasatinib, quercetin. Human trial data: senolytics (Justice 2019 IPF pilot; Hickson 2019 diabetic kidney disease pilot).

Step 3 — BH3-mimetics as senolytics

navitoclax (ABT-263), developed originally as an oncology drug targeting BCL-2/BCL-xL/BCL-w, was identified as a potent senolytic for IMR90 fibroblasts and HUVECs ³. The dose-limiting liability (thrombocytopenia from BCL-xL dependence in platelets) has prompted development of BCL-xL-targeting PROTACs designed to spare platelets (He et al. 2020 Nature Communications ⁸).

a1331852 (selective BCL-xL inhibitor) extends the BH3-mimetic senolytic toolkit with higher selectivity for the BCL-xL SCAP arm; see a1331852 for the mechanistic comparison with navitoclax. needs-human-replication

Step 4 — Flavonoid senolytics

fisetin (verified 2026-05-04) was identified as the most potent senolytic flavonoid in a screen of 10 flavonoids ⁹ and extended healthspan and median lifespan in aged C57BL/6 mice. Its SCAP mechanism is incompletely characterized relative to D+Q. Human Phase 2 trials are ongoing. Full data on fisetin.

Step 5 — FOXO4-p53 disruption

Baar et al. 2017 ¹⁰ demonstrated that a FOXO4-interfering peptide (FOXO4-DRI) selectively induces apoptosis in senescent cells by disrupting the FOXO4–p53 interaction that sequesters p53 in the nucleus, away from its pro-apoptotic mitochondrial function. This represents a mechanistically distinct SCAP arm — p53 retention in the nucleus as a survival mechanism rather than BCL-2 family upregulation.

Key cross-links: foxo4, p53, apoptosis-pathway § mitochondrial pathway.

needs-human-replication — FOXO4-DRI is preclinical only as of 2026; no human trials confirmed.

Evidence cluster

Framework-level summary of the evidence nodes. Do not re-read claims from here — follow the links.

Evidence node	Verification status	Page
Baker 2011 (INK-ATTAC genetic clearance, healthspan)	unverified — PDF not in archive (download failed)	cellular-senescence
Baker 2016 (INK-ATTAC, natural aging, lifespan)	verified — PDF in archive	cellular-senescence
Zhu 2015 (SCAP concept, D+Q, preadipocyte + HUVEC)	verified (senolytics page)	senolytics
Zhu 2016 (navitoclax senolytic, IMR90 triple BCL-2 requirement)	verified (senolytics page)	senolytics
Yosef 2016 (BCL-W + BCL-xL dual knockdown in IMR90)	not independently verified	bcl-w, bcl-xl
Baar 2017 (FOXO4-DRI peptide)	not independently verified — PDF in archive	foxo4
Yousefzadeh 2018 (fisetin, mouse lifespan)	verified (fisetin page + senolytics page)	fisetin, yousefzadeh-2018-fisetin-senolytic
Justice 2019 (D+Q IPF pilot, human)	verified (senolytics page)	senolytics
Hickson 2019 (D+Q diabetic kidney, human)	verified (senolytics page)	senolytics
He 2020 (PROTAC navitoclax, reduced platelet toxicity)	not independently verified — PDF in archive	navitoclax
Childs 2016 (atherosclerosis preclinical)	unverified — PDF not OA in archive	cellular-senescence

Relationship to the López-Otín hallmarks frame

ApoptoSENS and cellular-senescence cover overlapping biology but slice it differently:

Hallmarks frame is organized by type of damage and causal cascade: senescent cells are an Antagonistic hallmark — initially protective (tumor suppression, wound healing, developmental patterning), they become damaging when they chronically accumulate. The frame asks: what molecular lesions trigger senescence?
SENS / ApoptoSENS frame is organized by what repair is needed: the relevant fact is not why cells became senescent, but that they now resist death. The frame asks: how do we eliminate them?

These are complementary, not competing. The atomic pages (BCL-2 family proteins, sasp, cellular-senescence, individual senolytic compounds) are the single source of truth for all quantitative claims; both frameworks link to the same pages.

Crosswalk entry in hallmarks-of-aging table: Cellular senescence → [[sens-damage-categories#3-death-resistant-cells-apoptosenes]].

Open questions

Biomarkers for in vivo senescent cell burden — SA-β-gal is histology-only and not validated for blood or imaging. p16^INK4a^ mRNA in circulating PBMCs is used in trials but specificity is unclear. No validated clinical assay exists as of 2026. unsourced — needs primary reference for current state of clinical biomarker validation.

Tissue heterogeneity — which tissues accumulate the most senescent cells, and which cell-type SCAPs dominate in vivo, remains poorly mapped. The Zhu/Yosef data come from three in vitro cell lines; needs-replication in primary human tissue.

Dosing strategy: intermittent vs continuous — the hit-and-run model (senolytics dosed intermittently, e.g., 3 days per month, because senescent cells take weeks to repopulate) is now standard in trials, but optimal interval and duration are unknown. dose-response-unclear

Cancer risk of long-term senolytic use — senescent cells play a tumor-suppressive role in early oncogenesis. Chronic clearance might reduce this protection in some contexts. long-term-unknown — no long-duration human safety data.

Combination strategies — senolytics + senomorphics (sasp suppression, e.g., JAK inhibitors, rapamycin) may be complementary. Largely untested in humans. needs-human-replication

Footnotes

de-grey-2002-sens · doi:10.1111/j.1749-6632.2002.tb02115.x · review · model: conceptual framework · not in archive (not_oa); available via Wiley ↩
zhu-2015-scap-senolytics · doi:10.1111/acel.12344 · in-vitro · model: HUVECs + human preadipocytes · PDF in archive · verified on senolytics and dasatinib ↩ ↩² ↩³
zhu-2016-navitoclax-senolytic · doi:10.1111/acel.12445 · in-vitro · model: IMR90 fibroblasts + HUVECs · PDF in archive · verified on senolytics ↩ ↩²
yosef-2016-bcl-senescence · doi:10.1038/ncomms11190 · in-vitro · model: IMR90 fibroblasts · PDF in archive · not independently verified on this page — claims cross-referenced from bcl-w and bcl-xl ↩
sens-damage-categories § Status table — ApoptoSENS in clinical trials column; see senolytics for NCT details. ↩
baker-2011-ink-attac-clearance · doi:10.1038/nature10600 · in-vivo · model: BubR1-progeroid INK-ATTAC transgenic mice · PDF not in archive (download failed) · carried from cellular-senescence verification notes ↩
baker-2016-ink-attac-lifespan · doi:10.1038/nature16932 · in-vivo · model: naturally aged INK-ATTAC mice · PDF in archive · verified on cellular-senescence ↩
he-2020-protac-navitoclax · doi:10.1038/s41467-020-15838-0 · in-vivo · model: aged mice · PDF in archive · not independently verified on this page — see navitoclax ↩
yousefzadeh-2018-fisetin-senolytic · doi:10.1016/j.ebiom.2018.09.015 · in-vivo · model: aged C57BL/6 mice · PDF in archive · verified on fisetin ↩
baar-2017-foxo4-dri · doi:10.1016/j.cell.2017.02.031 · in-vivo · model: aged C57BL/6 mice · PDF in archive · not independently verified on this page ↩

🧬 Aging Wiki

Explorer

apoptosenes